

EN

E-004357/2025

Answer given by Mr Várhelyi
on behalf of the European Commission
(13.2.2026)

Within the EU framework for control measures and vaccination against lumpy skin disease (LSD)^{1 2 3} and in alignment with World Organisation for Animal Health standards⁴, emergency protective vaccination may be applied when epidemiologically justified. Member States, not the Commission, decide whether to introduce vaccination for Category A diseases such as LSD and determine its scope and geographical extent in their national vaccination plans.

The Commission coordinates Member States in outbreak management ensuring rapid regionalisation and adopting emergency measures protecting animal health. It also provides scientific, technical and diagnostic support through the EU Reference Laboratory and the EU Veterinary Emergency Team and upon request, in emergency situations, rapid vaccine access from the EU vaccine bank.

For additional details, the Commission would also like to refer to the answer to P-004478/2025 and P-004548/2025/rev.1⁵.

¹ OJ L 84, 31.3.2016, p. 1, ELI: <http://data.europa.eu/eli/reg/2016/429/oj>.

² Commission Delegated Regulation (EU) 2020/687 of 17 December 2019 supplementing Regulation (EU) 2016/429 of the European Parliament and the Council, as regards rules for the prevention and control of certain listed diseases *OJ L 174*, 3.6.2020, http://data.europa.eu/eli/reg_del/2020/687/oj.

³ Commission Delegated Regulation (EU) 2023/361 of 28 November 2022 supplementing Regulation (EU) 2016/429 of the European Parliament and the Council as regards rules for the use of certain veterinary medicinal products for the purpose of prevention and control of certain listed diseases (OJ L 52, 20.2.2023, p. 1, ELI: http://data.europa.eu/eli/reg_del/2023/361/oj).

⁴ <https://www.woah.org/en/what-we-do/standards/>.

⁵ https://www.europarl.europa.eu/doceo/document/P-10-2025-004478_EN.html,
https://www.europarl.europa.eu/doceo/document/P-10-2025-004548_EN.html.